190 related articles for article (PubMed ID: 18622261)
21. Genetic variations and haplotypes of UGT1A4 in a Japanese population.
Saeki M; Saito Y; Jinno H; Sai K; Hachisuka A; Kaniwa N; Ozawa S; Kawamoto M; Kamatani N; Shirao K; Minami H; Ohtsu A; Yoshida T; Saijo N; Komamura K; Kotake T; Morishita H; Kamakura S; Kitakaze M; Tomoike H; Sawada J
Drug Metab Pharmacokinet; 2005 Apr; 20(2):144-51. PubMed ID: 15855727
[TBL] [Abstract][Full Text] [Related]
22. Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver.
Mano Y; Usui T; Kamimura H
Drug Metab Dispos; 2007 Jul; 35(7):1182-7. PubMed ID: 17446261
[TBL] [Abstract][Full Text] [Related]
23. Lack of genetic association between OCT1, ABCB1, and UGT2B7 variants and morphine pharmacokinetics.
Nielsen LM; Sverrisdóttir E; Stage TB; Feddersen S; Brøsen K; Christrup LL; Drewes AM; Olesen AE
Eur J Pharm Sci; 2017 Mar; 99():337-342. PubMed ID: 28063968
[TBL] [Abstract][Full Text] [Related]
24. Expression of UGT2B7 is driven by two mutually exclusive promoters and alternative splicing in human tissues: changes from prenatal life to adulthood and in kidney cancer.
Ménard V; Lévesque E; Chen S; Eap O; Joy MS; Ekström L; Rane A; Guillemette C
Pharmacogenet Genomics; 2013 Dec; 23(12):684-96. PubMed ID: 24128937
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism.
Court MH; Krishnaswamy S; Hao Q; Duan SX; Patten CJ; Von Moltke LL; Greenblatt DJ
Drug Metab Dispos; 2003 Sep; 31(9):1125-33. PubMed ID: 12920168
[TBL] [Abstract][Full Text] [Related]
26. UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease.
Darbari DS; van Schaik RH; Capparelli EV; Rana S; McCarter R; van den Anker J
Am J Hematol; 2008 Mar; 83(3):200-2. PubMed ID: 17724700
[TBL] [Abstract][Full Text] [Related]
27. Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies.
Chau N; Elliot DJ; Lewis BC; Burns K; Johnston MR; Mackenzie PI; Miners JO
J Pharmacol Exp Ther; 2014 Apr; 349(1):126-37. PubMed ID: 24459244
[TBL] [Abstract][Full Text] [Related]
28. Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen.
Wang H; Yuan L; Zeng S
Biochem Pharmacol; 2011 Dec; 82(11):1757-63. PubMed ID: 21856293
[TBL] [Abstract][Full Text] [Related]
29. Induction of human UDP-Glucuronosyltransferase 2B7 gene expression by cytotoxic anticancer drugs in liver cancer HepG2 cells.
Hu DG; Mackenzie PI; Lu L; Meech R; McKinnon RA
Drug Metab Dispos; 2015 May; 43(5):660-8. PubMed ID: 25713207
[TBL] [Abstract][Full Text] [Related]
30. Homo- and hetero-dimerization of human UDP-glucuronosyltransferase 2B7 (UGT2B7) wild type and its allelic variants affect zidovudine glucuronidation activity.
Yuan L; Qian S; Xiao Y; Sun H; Zeng S
Biochem Pharmacol; 2015 May; 95(1):58-70. PubMed ID: 25770680
[TBL] [Abstract][Full Text] [Related]
31. Modulation of the UGT2B7 enzyme activity by C-terminally truncated proteins derived from alternative splicing.
Ménard V; Collin P; Margaillan G; Guillemette C
Drug Metab Dispos; 2013 Dec; 41(12):2197-205. PubMed ID: 24088326
[TBL] [Abstract][Full Text] [Related]
32. Variability in UDP-glucuronosyltransferase genes and morphine metabolism: observations from a cross-sectional multicenter study in advanced cancer patients with pain.
Fladvad T; Klepstad P; Langaas M; Dale O; Kaasa S; Caraceni A; Skorpen F
Pharmacogenet Genomics; 2013 Mar; 23(3):117-26. PubMed ID: 23277092
[TBL] [Abstract][Full Text] [Related]
33. Epirubicin upregulates UDP glucuronosyltransferase 2B7 expression in liver cancer cells via the p53 pathway.
Hu DG; Rogers A; Mackenzie PI
Mol Pharmacol; 2014 Jun; 85(6):887-97. PubMed ID: 24682467
[TBL] [Abstract][Full Text] [Related]
34. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.
Lévesque E; Delage R; Benoit-Biancamano MO; Caron P; Bernard O; Couture F; Guillemette C
Clin Pharmacol Ther; 2007 Mar; 81(3):392-400. PubMed ID: 17339869
[TBL] [Abstract][Full Text] [Related]
35. Octamer transcription factor-1 enhances hepatic nuclear factor-1alpha-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter.
Ishii Y; Hansen AJ; Mackenzie PI
Mol Pharmacol; 2000 May; 57(5):940-7. PubMed ID: 10779377
[TBL] [Abstract][Full Text] [Related]
36. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients.
Djebli N; Picard N; Rérolle JP; Le Meur Y; Marquet P
Pharmacogenet Genomics; 2007 May; 17(5):321-30. PubMed ID: 17429314
[TBL] [Abstract][Full Text] [Related]
37. A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer.
Sawyer MB; Pituskin E; Damaraju S; Bies RR; Vos LJ; Prado CM; Kuzma M; Scarfe AG; Clemons M; Tonkin K; Au HJ; Koski S; Joy AA; Smylie M; King K; Carandang D; Damaraju VL; Hanson J; Cass CE; Mackey JR
Clin Breast Cancer; 2016 Apr; 16(2):139-44.e1-3. PubMed ID: 26452313
[TBL] [Abstract][Full Text] [Related]
38. Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver.
Ramírez J; Mirkov S; Zhang W; Chen P; Das S; Liu W; Ratain MJ; Innocenti F
Pharmacogenomics J; 2008 Apr; 8(2):152-61. PubMed ID: 17440429
[TBL] [Abstract][Full Text] [Related]
39. Association between UDP-glucuronosyltransferase 2B7 tagSNPs and breast cancer risk in Chinese females.
He BX; Qiao B; Lam AK; Zhao XL; Zhang WZ; Liu H
Clin Exp Pharmacol Physiol; 2018 May; 45(5):437-443. PubMed ID: 29272031
[TBL] [Abstract][Full Text] [Related]
40. The pharmacokinetics of morphine and its glucuronide conjugate in a rat model of streptozotocin-induced diabetes and the expression of MRP2, MRP3 and UGT2B1 in the liver.
Hasegawa Y; Kishimoto S; Shibatani N; Nomura H; Ishii Y; Onishi M; Inotsume N; Takeuchi Y; Fukushima S
J Pharm Pharmacol; 2010 Mar; 62(3):310-4. PubMed ID: 20487213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
